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accepted Octoberoronary spasm is an important and often overlooked etiology of chest pain. Although coronary spasm, or
Prinzmetal’s angina, has been thought of as benign, contemporary studies have shown serious associated adverse
outcomes, including acute coronary syndrome, arrhythmia, and death. Deﬁnitive diagnosis of coronary spasm can at
times be difﬁcult, given the transience of symptoms. Numerous agents have been historically described for
provocative testing. We provide a review of published data for the role of provocation testing in the diagnosis of
coronary spasm. (J Am Coll Cardiol 2014;63:103–9) ª 2014 by the American College of Cardiology FoundationCoronary spasm (CS) is an important etiology of angina that
often goes undiagnosed. Although older published data
suggest that the prognosis for patients with coronary spasm
is relatively benign (1), contemporary reports indicate that
CS has been associated with ischemia, acute coronary
syndrome, arrhythmia, and sudden cardiac arrest (SCA)
(2–4), with a worse prognosis reported in those with even
trivial coronary stenosis (5). Diagnosis can be difﬁcult, given
the transience of CS, and might require more sophisticated
provocative diagnostic approaches. In current U.S. practice,
it seems provocation testing in the cardiac catheterization
laboratory is performed less frequently, although quantitative
data are not available. Numerous agents have been described
for spasm provocation testing including ergonovine (ER),
acetylcholine (ACH), neuropeptide Y, and dopamine (6–9);
however, a relatively larger body of evidence supports ER
and ACH for clinical practice. We herein review provocative
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The pharmacological agents most often used clinically in
provocation testing for the diagnosis of CS are ER (6,10–20)
and ACH (1,8,21–23). Ergonovine acts on smooth muscle
mainly via activation of serotonergic (5-HT2) receptors to
produce vasoconstriction (24). Activation of the endothe-
lium in response to ER also causes release of inhibitory
prostanoid substances; those with endothelial dysfunction
might have more pronounced contraction (24). Ergonovine
is predominantly metabolized by the liver and serves as
a major substrate of CYP3A4 hepatic enzymes. Adverse
reactions to ergot alkaloids are diverse and include angina,
ischemia, myocardial infarction (MI), arrhythmia, nausea,
allergic reaction, and ergotism (18,25).
ACH acts on the endothelium and smooth muscle via
muscarinic receptors. In healthy endothelium, ACH acti-
vation results in vasodilation. However, in the setting of
endothelial dysfunction, endothelial cells insufﬁciently
produce nitric oxide, a potent smooth muscle relaxant (26)
resulting in blood vessel contraction rather than vasodila-
tion. Adverse reactions to ACH include hypotension,
bradycardia, dyspnea, and ﬂushing (27). When using
intracoronary (IC) ACH, the risk of bradyarrhythmia is
often circumvented with temporary ventricular pacing.
Serious reactions include ventricular tachycardia, shock, and
cardiac tamponade (28).
Both ACH and ER are not U.S. Food and Drug
Administration-approved for the indication of coronary
vasospasm diagnosis. Various testing protocols using IC
and intravenous (IV) administration have been described
(Table 1). Importantly, induction of spasm with IV ER can
produce multivessel spasm and hemodynamic instability,
making arteriograms difﬁcult to obtain. Furthermore, IC
nitroglycerin might be required to relieve spasm. For these
reasons, Hackett et al. (6) demonstrated that induction of
Table 1
Firs
Invasive
Akasaka
Bertrand
Hackett
Harding
Japanese
Okumura
Song et
Sueda et
Takagi e
Waters e
Yasue et
Noninvasive
Song et
ER¼ ergonovin
Abbreviations
and Acronyms
ACH = acetylcholine
CFR = coronary ﬂow reserve
CS = coronary spasm
ER = ergonovine
IC = intracoronary
IV = intravenous
MI = myocardial infarction
SCA = sudden cardiac arrest
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104CS with IC ER might be safer
than IV administration. Addi-
tionally, IC (ER or ACH) admi-
nistration allows provocation of
the right and left coronaries sepa-
rately. Furthermore, although IV
ER provocation testing has good
sensitivity (100% with angina as
part of the diagnostic criteria, and
94% with ST-segment elevation)
(17), reports show frequency of
provokedCSwith ICER to be 2.2to 2.6 times higher than IV testing (23). Speciﬁcity of IV and
IC ER provocation testing are similarly high, >90% (6,11).
Despite high sensitivity, false negatives have been reported
(29); thus, a negative test cannot always exclude CS.
Pathogenesis of CS
The role of CS in variant angina, or Prinzmetal’s angina, is
well documented (30). Patients have spontaneous angina
episodes associated with reversible constriction of a focal
segment or segments of coronary artery leading to restriction
of coronary blood ﬂow and myocardial ischemia. These
episodes are often associated with ST-segment elevation
(31). Spasm can involve the epicardial coronary vessels, but
coronary microvascular spasm can also occur and might be
associated with cardiac syndrome X (32).
The pathogenesis of CS is likely multifactorial and
heterogeneous among different populations. Coronary vas-
cular smooth muscle hyper-reactivity (33) has been descri-
bed and is thought to be a consequence of loss of balance
between vascular myosin light chain kinase and phosphatase
activity, leading to a predominance of myosin light chainProvocation Testing Dosing Protocols
t Author (Ref. #) Ergot Derivativ
et al. (10) ER 100 mg IV (up to 200
et al. (11) Methergine 400 mg IV
et al. (6) ER 6–50 mg IC
et al. (12) ER 50–150 mg IV
Circulation Society (45) ER 20–60 mg (LCA, IC);
ER 20–60 mg (RCA, IC
et al. (8,22) 200 mg IV
al. (19) ER 1–30 mg IC
al. (13–16,23) ER 40 mg (RCA, IC); 64 m
t al. (18) ER 20–60 mg (LCA, IC);
ER 20–60 mg (RCA, IC
t al. (17) ER 12.5–400 mg IV
al. (21) N/A
al. (20) ER 25–50 mg IV (up to 3
e maleate; IC ¼ intracoronary; IV¼ intravenous; LCA¼ left corphosphorylation and resultant excessive vascular smooth
muscle contraction (34). Endothelial cell dysfunction also
contributes, as these cells act as paracrine regulators of vascu-
lar tone and respond to changes in shear stress, myogenic
constriction, and vasoactive substances by releasing various
vasorelaxant substances (35,36). Prior work has demonstrated
that ACH-induced dilation is lost in the presence of athero-
sclerosis in the coronaries of human transplanted hearts (37).
Interestingly, differing pathophysiology has been pro-
posed for focal and diffuse vasospasm. Atherosclerotic
lesions have been identiﬁed at the site of focal spasm with
intravascular ultrasound (38). Akasaka et al. (10) compared
coronary ﬂow reserve (CFR) of patients with focal versus
diffuse spasm and found that patients with ER-induced
diffuse spasm had signiﬁcantly reduced CFR compared
with control (normal coronaries, no spasm). In contrast,
those with focal ER-induced spasm maintained normal
CFR. They suggested that focal spasm might be related
to localized epithelial dysfunction of the epicardial coro-
naries without signiﬁcant effect on coronary microvascular
function.
Variant angina episodes occur most from midnight to
early morning when vagal tone is highest. Increased vagal
tone and hyper-reactivity to sympathetic stimulation have
been described in the mechanism, with some even reporting
surgical sympathetic denervation as a therapeutic option for
medically refractory patients (39).
Environmental factors such as smoking (1,40), metabolic
abnormalities (41), and alcohol consumption (1) might also
be pathogenic contributors. Racial variations in incidence
have been reported (42), with a higher prevalence found in
Japanese than Western individuals (11,23,43), suggesting
genetic differences in addition to differences in environ-
mental exposures. Several single nucleotide polymorphismse Acetylcholine
mg) N/A
N/A
N/A
N/A
)
20–100 mg (LCA, IC); 20–50 mg (RCA, IC)
20–100 mg (LCA, IC); 20–50 mg (RCA, IC)
10–100 mg IC
g (LCA, IC) 20–100 mg (LCA, IC); 20–80 mg (RCA, IC)
)
20–100 mg (LCA, IC); 20–50 mg (RCA, IC)
N/A
Suspected vessel: 10–100 mg IC;
contralateral artery: 20–100 mg (LCA, IC);
20–50 mg (RCA, IC)
50 mg total) N/A
onary artery; NSS¼ normal saline solution; RCA¼ right coronary artery.
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105have been identiﬁed (44) that are thought to be related
to CS.Provocation Testing
Invasive. A positive response to ACH or ER spasm
provocation testing is deﬁned as transient occlusion (>90%
narrowing) of a coronary artery with signs and symptoms
of myocardial ischemia (angina/ST-segment changes) (45).
The incidence of positive testing depends on the pop-
ulation. Bertrand et al. (11) conducted a large French
cohort study with 1,089 patients who underwent ER
provocation testing during routine coronary angiography
for suspected ischemia. They found that 12.3% of patients
developed CS. Provoked spasm was most common in
patients with rest angina (38%) and recent MI (20%) and
less in those with exertional symptoms (4.3%) and atypi-
cal angina (1.2%). Notably, 59% of vasospasm episodes
occurred on pre-existing ﬁxed stenoses. Harding et al. (12)
conducted a large North American study evaluating 3,447
patients with nonobstructive coronary disease (<50%
stenosis) and without previously documented Prinzmetal’s
angina. These investigators reported 4% positive invasive
ER testing. In comparison with the study by Bertrand et al.
(11), lower doses of ER were used. After multivari-
ate analysis, degree of coronary disease on angiography
and smoking were statistically signiﬁcant predictors of
spasm (12).Table 2 Practice Guidelines for Coronary Spasm
Guidelines (Ref. #) Classiﬁ
2006 European Society of Cardiology stable angina
guidelines (55)
II
2008 Japanese Circulation Society vasospastic
angina guidelines (45)
I
2011 ACCF/AHA unstable angina/non-STEMI
guidelines (54)
II
2011 ACCF/AHA/SCAI percutaneous coronary
intervention guidelines (56)
d
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS stable
ischemic heart disease guidelines (57)
d
2012 ACCF/AHA unstable angina/non-STEMI
guidelines (58)
d
AATS ¼ American Association for Thoracic Surgery; ACCF ¼ American Colle
AHA ¼ American Heart Association; CAD ¼ coronary artery disease; ECG
PCNA ¼ Preventive Cardiovascular Nurses Association; SCAI ¼ Society for
elevation myocardial infarction; STS ¼ Society of Thoracic Surgeons.Yasue et al. (21) evaluated the sensitivity of IC ACH in
provoking CS. All 27 patients studied had CS on the basis
of rest angina symptoms with associated ST-segment
changes. Injection of ACH into the suspected coronary
artery induced spasm in 30 of 32 (94%) arteries in 25 of 27
(93%) patients. One-half of the coronary arteries tested not
suspected to be responsible for the attacks showed 25% to
75% luminal narrowing, without chest pain or ST-segment
changes, suggesting that the testing had good sensitivity
and speciﬁcity (21). Okumura et al. (22) examined the
effect of IC ACH testing in 70 patients with variant
angina and 93 patients without variant or rest angina and
reported 90% sensitivity and 99% speciﬁcity. In a larger
study, Sueda et al. (23) explored the incidence of spasm
with IC ACH testing in 685 patients undergoing angi-
ography and found CS in 221 patients (32.3%). More
provoked spasm was seen in patients with rest angina
(83 of 125, 66.9%), similar to ER provocation studies,
and least in those with atypical angina (4 of 83, 4.8%).
Spasm was also more common in patients with prior MI
and atherosclerosis, although those with advanced athe-
rosclerosis were excluded (23).
Ergonovine testing is often compared with or used in
combination with ACH. Sueda et al. (13) performed IC
administration of both ACH and ER in the same 171
patients, all of whom had <50% stenosis. They found no
signiﬁcant differences in provoked spasm between the 2
agents (ACH: 33% vs. ER: 32%, p ¼ NS). Notably, ACHProvocation Testing
cation
Level of
Evidence Recommendations
a B IC provocation testing
known anatomy,
nonobstructive CAD
d IC provocation testing during
angiography
in patients with suspected
variant angina without
a diagnosis
by noninvasive measures
(ECG, Holter, exercise,
hyperventilation)
recommended protocol
provided in Table 1
b C Provocation testing indicated
known coronary anatomy
failed empiric treatment
life-threatening disease and
veriﬁcation of spasm is
necessary
d None
d None
d None
ge of Cardiology Foundation; ACP ¼ American College of Physicians;
¼ electrocardiogram; IC ¼ intracoronary; MI ¼ myocardial infarction;
Cardiovascular Angiography and Interventions; STEMI ¼ ST-segment
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106provoked more diffuse and distal spasm, whereas ER induced
more focal spasm. No serious or irreversible complications
were observed. In a subsequent study in 2004, the same
Japanese investigators retrospectively analyzed 1,508 selective
spasm provocation tests (873 ACH, 635 ER) (14). They
found no difference between the agents in patients with
ischemic heart disease but found signiﬁcantly higher
provoked spasm with ACH than ER in patients with no
coronary artery disease (11.0% vs. 6.4%, p < 0.05). Addi-
tionally, multiple spasm as well as spasm not associated with
focal stenosis was provoked more with ACH. More compli-
cations were seen with ACH compared with ER (1.4% vs.
0.2%); however, none were serious (death,MI) or irreversible.
Sueda et al. (15) also investigated the usefulness of
combined provocation testing with ACH and ER. Three
sequential provocation tests were performed with ACH, then
ER, followed by a combination test using sequential IC
injections of both agents, eliminating patients with positive
spasm between tests. In this study, signiﬁcantly more
spasm was induced in patients with rest angina and ische-
mia (98% with provoked spasm) compared with patients withFigure 1 Coronary Spasm
Angiogram before (A) and after (B) administration of 200 mg intravenous ergonovine show
Adlam et al. (59). Angiogram before (C) and after (D) intracoronary infusion of acetylcholin
left anterior descending artery.atypical angina and no ischemia (8% with provoked spasm).
Ischemia was deﬁned as electrocardiogram changes or
abnormal scintigraphy during exercise. In those with rest
angina, ACHprovoked spasm in 55%, ER provoked spasm in
33%, and the combination test provoked spasm in 92% of the
remaining patients. No major complications were reported.
Sueda et al. (16). additionally studied whether the CS
induced by provocation testing correlated with the angina-
provoking artery responsible for the sites of ST-segment
elevation during ischemic attacks. They evaluated 42 pati-
ents, predominantly men, with variant angina and history
of a recent ST-segment elevation myocardial infarction
attributed to spasm. The correlation with the ACH test
was 78.6% for all patients and 80.0% for all sites of
ST-segment elevation. By adding the ER test after the
ACH test, the correlation increased to 95.2% for all pati-
ents and 95.6% for all sites of ST-segment elevation.
A particularly important population in which diagnostic
testing for CS might be critical are survivors of SCA who
have no apparent cardiac disease. Studies demonstrate that
CS might trigger lethal arrhythmias and lead to SCA (3,46).ing focal spasm of the left anterior descending artery. Reprinted with permission from
e at a concentration of 0.182 mg/ml (2 ml over 3 min) showing diffuse spasm of the
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107Igarashi et al. (47) studied 14 survivors of SCA without
apparent heart disease. Overall, 4 were found to have angina
with ST-segment elevation during observation; 5 of the
remaining 9 had positive ER provocation testing. Survivors
who underwent subsequent diagnostic spasm provocation
testing and appropriate therapy seem to have a good prog-
nosis. Chevalier et al. (48) followed 7 survivors of SCA (with
absence of known heart disease) who underwent ER prov-
ocation testing that was positive. Treatment with a calcium
channel blocker was initiated at a dose determined by
titration until a negative provocation test resulted. All were
habitual smokers. In 58 months of follow-up, only the
patient who did not abstain from tobacco had a recurrent
event, highlighting treatment efﬁcacy and importance of risk
management (48). Studies indicate that severe multivessel
spasm, daytime ST-segment changes, and younger age are
predictors of SCA (3). Additionally, Togashi et al. (4) have
reported differing circadian variance in patients with SCA
and syncope triggered by CS relative to patients with typical
CS (nocturnal symptoms, angina only), suggesting possible
differences in pathogenesis and need for provocation testing
even in those without typical variant angina.Figure 2 Variant Angina Algorithm
Suspicion is based on clinical factors: spontaneous episodes of angina occurring at rest
tolerance (reduced during early morning hours); quick relief of angina with nitrates; suppre
ACH ¼ acetylcholine; CAD ¼ coronary artery disease; ECG ¼ electrocardiogram; ER ¼ erNoninvasive. Noninvasive, nonpharmacological evaluation
for the diagnosis of CS includes standard 12-lead electro-
cardiogram (during attack), Holter monitoring (45), exercise
testing (49), and hyperventilation testing (50). Waters et al.
(17) reported better sensitivity with pharmacological testing
(IV ER) compared with noninvasive, nonpharmacological
measures in patients with untreated variant angina. The ER
testing induced angina in all 34 patients and ST-segment
elevation in 32 (94%), exercise testing induced angina in
17 (50%) and ST-segment elevation in 10 (29%), and cold
pressor testing provoked angina in 5 (15%) and ST-segment
elevation in 3 (9%) (17). Conversely, Okumura et al. (8)
reported 93% sensitivity with exercise myocardial scintig-
raphy and echocardiography during the hyperventilation
provocation test in predicting IC ACH spasm. Sueda et al.
(51) assessed the usefulness of a combined hyperventilation
and exercise test and reported 64.9% sensitivity and 100%
speciﬁcity.
There is a relative paucity of published data with regard
to the safety of bedside ER provocation testing for CS.
Protocols using continuous monitoring of wall motion
by echocardiography to detect spasm-induced ischemia inand between night and early morning hours; marked diurnal variation in exercise
ssion of attacks with calcium channel blockers (CCBs); smoking; and Asian descent.
gonovine.
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108patients with near-normal angiographic ﬁndings are des-
cribed (20). The safety of bedside ER stress echocardiog-
raphy is reported by Song et al. (19) in a retrospective
analysis of 1,372 patients without signiﬁcant myocardial
ischemia (most evaluated by exercise stress testing). Overall,
31% of the patients had positive results, arrhythmia devel-
oped in 1.9%, and all episodes were transient and reversible.
No mortality or MI was reported. Of the 16% of patients
who also underwent invasive CS testing, the investigators
reported agreement between tests in 93% of the patients,
suggesting similar diagnostic accuracy. Speciﬁcity was 91%
(19). The accuracy of bedside ER testing among patients
without prior coronary angiography might be less diagnostic
for spasm, due to provocation of occult obstructive coronary
disease-related ischemia.
Safety and Practice Guidelines
Contemporary reports suggest that provocation testing is
relatively safe (18); however, there are older reports of refrac-
tory spasm and recurrent spasm resulting in prolonged
ischemia, MI, and death (52,53). A recent observational
study evaluated 1,244 patients with vasospastic angina
who underwent IC provocation tests (40% ER, 57% ACH,
2% ERþACH, 1% other) (18). The overall incidence of
arrhythmic complications was 6.8%, which is comparable
to 7.0% during spontaneous angina events. They reported
a 5.5% major adverse cardiovascular event rate during the
32-month follow-up period. After multivariable analysis,
mixed (focal and diffuse) multivessel spasm predicted
major adverse cardiovascular events (adjusted hazard ratio:
2.84; 95% conﬁdence interval: 1.43 to 6.03, p < 0.01),
but provocation-related arrhythmiasddeﬁned as ventri-
cular tachycardia, ventricular ﬁbrillation, and bradyar-
rhythmiasddid not (18).
Prior American College of Cardiology/American Heart
Association guidelines support limited use of provocative
testing for spasm (54); however, current guidelines do not
address this generally or speciﬁcally (e.g., invasive vs. nonin-
vasive, ER vs. ACH, IC vs. IV administration) (56–58),
whereas other international practice guidelines do (Table 2).
Conclusions
Provocative testing is effective for diagnosis of CS. Testing
might be appropriate in properly-equipped facilities with
experienced physicians for patients without obstructive coro-
nary artery disease presenting with suspected variant angina,
as outlined in our recommended algorithm (Figs. 1 and 2) (59).
Both ACH and ER seem to have comparable diagnostic
yield. With ER provocation testing, IC testing rather than
IV is useful in identifying the culprit vasospastic vessel and
allows for treatment of refractory spasm. There is a paucity of
safety data on the use of bedside ER provocation testing with
echocardiography monitoring. Larger, ethnically-diverse
studies that include more women are needed to generateevidence-based guidelines with regard to the effectiveness
and safety of ER and ACH provocation testing for the
diagnosis of CS.
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